Ginkgo Bioworks (NYSE:DNA) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel. Now, this doesn’t mean that there aren’t any more shore shares available, as Fintel doesn’t sample every single brokerage. But it does show a clear surge in the ...

BOSTON, April 29, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of Myrtle Potter and Ross Fubini for election as independent directors at Ginkgo's upcoming annual meeting, scheduled to be held on June 13, 2024. Marijn Dekkers, who has served on Ginkgo's Board since 2019 and as Ginkgo's Board Chair from 2019 through 2023, and Reshma Kewalramani, who joined Ginkgo's Board in 2021 and serves as Nomi ...

IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture productPADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration. IGDI has identified a new sourdough bakery strain that can improve the flavo ...

BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated into Ginkgo Ag Biologicals Services, established with the acquisition of a Bayer agri ...

BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.  Novo Nordisk Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo ...

These stocks, a bargain today, are players to hold on to for the long term.The S&P 500 roared to a record high earlier this year, confirming we are indeed in a bull market, and that's great news for growth stocks. These market environments favor companies that are expanding rapidly and investing to build their businesses. Some of these players have benefited, leading gains in the broader market, but others have been left behind, even though they offer exciting long-term prospects.And these are the players t ...

Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosec ...

BOSTON, April 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the Ginkgo community, from shareholders and customers to suppliers, academics, and many more. Ginkgo Ferment 2024 Because we have reached in-person capacity, a video livestream of the e ...

The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturingNORTHUMBERLAND, England and BOSTON, April 3, 2024 /PRNewswire/ -- Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, Ginkgo and Prozomix aim ...

Human Natural Killer cell. (National Institute of Allergy and Infectious Diseases Image)The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks. The companies did not disclose the terms of the acquisition. An article by Fierce Biotech noted that Ginkgo’s business development team has snapped up a string of companies and assets in ...